This study investigated the capacity of a novel ruthenium complex [Ru(η6-cymene)2-(1H-benzoimidazol-2-yl)-quinoline Cl]BF4 (TQ-6) to prevent LPS-induced inflammation in microglia, MCAO-induced ischemic stroke, and platelet activation in mice; additionally, it elucidated the underlying defensive mechanisms of TQ-6 by examining the participation of NF-κB and Nrf2/HO-1 signaling molecules in these experiments. This evidence concerns the gene NFKB1 and ischemic stroke.